Glassia
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 20/100
20
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute-graft-versus-host Disease
Conditions
Acute-graft-versus-host Disease, Steroid Refractory Acute Graft Versus Host Disease, Graft-versus-host-disease, Graft Vs Host Disease, Alpha 1-Antitrypsin Deficiency, Alpha-1 Proteinase Inhibitor, Alpha-1 Protease Inhibitor Deficiency, Acute Graft-Versus-Host Reaction Following Bone Marrow Transplant
Trial Timeline
— → —
NCT ID
NCT03172455About Glassia
Glassia is a pre-clinical stage product being developed by Kamada for Acute-graft-versus-host Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT03172455. Target conditions include Acute-graft-versus-host Disease, Steroid Refractory Acute Graft Versus Host Disease, Graft-versus-host-disease.
Hype Score Breakdown
Clinical
3
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03172455 | Pre-clinical | Completed |
Competing Products
2 competing products in Acute-graft-versus-host Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| EQ001 + EQ001 Placebo | Biocon | Phase 1/2 | 32 |
| AAT + Placebo | CSL | Phase 2/3 | 42 |